Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Capecitabine
Roche Products Ltd
L01BC06
Capecitabine
150mg
Tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 08010300; GTIN: 5000471004991
1 uk-mt-pil-xeloda-clean-180316-150-500-tabs PACKAGE LEAFLET: INFORMATION FOR THE USER XELODA 150 MG FILM-COATED TABLETS XELODA 500 MG FILM-COATED TABLETS capecitabine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet (see section 4). WHAT IS IN THIS LEAFLET 1. What Xeloda is and what it is used for 2. What you need to know before you take Xeloda 3. How to take Xeloda 4. Possible side effects 5. How to store Xeloda 6. Contents of the pack and other information 1. WHAT XELODA IS AND WHAT IT IS USED FOR Xeloda belongs to the group of medicines called "cytostatic medicines", which stop the growth of cancer cells. Xeloda contains capecitabine, which itself is not a cytostatic medicine. Only after being absorbed by the body is it changed into an active anti-cancer medicine (more in tumour tissue than in normal tissue). Xeloda is used in the treatment of colon, rectal, gastric, or breast cancers. Furthermore, Xeloda is used to prevent new occurrence of colon cancer after complete removal of the tumour by surgery. Xeloda may be used either alone or in combination with other medicines. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE XELODA DO NOT TAKE XELODA: if you are allergic to capecitabine or any of the other ingredients of this medicine (listed in section 6). You must inform your doctor if you know that you have an allergy or over-reaction to this medicine, if you previously have had severe reactions to fluoropyrimidine therapy (a group of anticancer medicines such as fluorouracil), if you are pregnant orbreast-feeding, if you ha Read the complete document
OBJECT 1 XELODA 150MG AND 500MG FILM-COATED TABLETS Summary of Product Characteristics Updated 30-Apr-2018 | Roche Products Limited 1. Name of the medicinal product Xeloda 150 mg film-coated tablets. Xeloda 500 mg film-coated tablets. 2. Qualitative and quantitative composition Xeloda 150 mg film-coated tablets Each film-coated tablet contains 150 mg capecitabine. Xeloda 500 mg film-coated tablets Each film-coated tablet contains 500 mg capecitabine Excipient(s) with known effect _Xeloda 150 mg film-coated tablets _ Each 150 mg film-coated tablet contains 15.6 mg anhydrous lactose. _Xeloda 500 mg film-coated tablets_ Each 500 mg film-coated tablet contains 52 mg anhydrous lactose. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Film-coated tablet Xeloda 150 mg film-coated tablets The film-coated tablets are light peach tablets of biconvex, oblong shape with the marking '150' on the one side and 'Xeloda' on the other side Xeloda 500 mg film-caoted tablets The film-coated tablets are peach tablets of biconvex, oblong shape with the marking '500' on the one side and 'Xeloda' on the other side. 4. Clinical particulars 4.1 Therapeutic indications Xeloda is indicated for the treatment of: -for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer (see section 5.1). - metastatic colorectal cancer (see section 5.1). - first-line treatment of advanced gastric cancer in combination with a platinum-based regimen (see section 5.1). - in combination with docetaxel (see section 5.1) for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. - as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. 4.2 Posology and method of administration Xeloda should only be prescribed Read the complete document